SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-102187"
 

Sökning: id:"swepub:oai:DiVA.org:oru-102187" > Model-based predict...

  • Nilsson, KristofferThe Swedish Institute for Health Economics, Lund, Sweden (författare)

Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2022-12-02
  • Wiley-Blackwell Publishing Inc.2023
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-102187
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-102187URI
  • https://doi.org/10.1111/dom.14921DOI
  • https://lup.lub.lu.se/record/1c4b9a3a-5abc-4162-b9c7-8530e8627b2eURI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding agency:Boehringer Ingelheim
  • AIM: To perform a model-based analysis of the short- and long-term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden.MATERIALS AND METHODS: The validated Institute for Health Economics Diabetes Cohort Model (IHE-DCM) was used to estimate health benefits and 3-years' budget impact, and lifetime costs per quality-adjusted life year (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n=131,412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results.RESULTS: Over 3 years, SoC with empagliflozin (100% implementation) vs. SoC before empagliflozin resulted in 7,700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 6% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost-effectiveness ratio of €16,000 EUR per QALY vs. SoC before empagliflozin.CONCLUSIONS: Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even in a short-term perspective.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Andersson, EmelieThe Swedish Institute for Health Economics, Lund, Sweden (författare)
  • Persson, SofieLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)med-sep (författare)
  • Karlsdotter, KristinaBoehringer Ingelheim AB, Stockholm, Sweden(Swepub:lu)med-kkd (författare)
  • Skogsberg, JosefinBoehringer Ingelheim AB, Stockholm, Sweden (författare)
  • Gustavsson, StaffanBoehringer Ingelheim AB, Stockholm, Sweden (författare)
  • Jendle, Johan,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Boehringer Ingelheim AB(Swepub:oru)jje (författare)
  • Steen Carlsson, KatarinaLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)smi-ks0 (författare)
  • The Swedish Institute for Health Economics, Lund, SwedenHälsoekonomi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Diabetes, obesity and metabolism: Wiley-Blackwell Publishing Inc.25:3, s. 748-7571462-89021463-1326

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy